ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 128 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $778,166 | +9.3% | 113,601 | +29.1% | 0.00% | – |
| Q2 2023 | $712,049 | 0.0% | 88,016 | 0.0% | 0.00% | – |
| Q1 2023 | $712,049 | -48.6% | 88,016 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $1,386,253 | -99.9% | 88,016 | +1.5% | 0.00% | 0.0% |
| Q3 2022 | $1,364,753,000 | +13.3% | 86,706 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $1,204,288,000 | +41.6% | 86,267 | +74.8% | 0.00% | – |
| Q1 2022 | $850,726,000 | +18.6% | 49,346 | 0.0% | 0.00% | – |
| Q4 2021 | $717,491,000 | +9.3% | 49,346 | +35.3% | 0.00% | – |
| Q3 2021 | $656,388,000 | +19.5% | 36,466 | +16.6% | 0.00% | – |
| Q2 2021 | $549,276,000 | +706.6% | 31,280 | +175.2% | 0.00% | – |
| Q1 2019 | $68,094,000 | -71.1% | 11,368 | +18.8% | 0.00% | – |
| Q4 2017 | $235,947,000 | -96.1% | 9,568 | -95.9% | 0.00% | -100.0% |
| Q3 2017 | $6,029,113,000 | +102.0% | 233,596 | +112.3% | 0.01% | +66.7% |
| Q2 2017 | $2,984,204,000 | – | 110,037 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |